Soligenix, Inc. (NASDAQ:SNGX) – Equities research analysts at Zacks Investment Research raised their FY2021 earnings per share (EPS) estimates for Soligenix in a report issued on Monday, November 22nd. Zacks Investment Research analyst D. Bautz now forecasts that the biopharmaceutical company will earn ($0.31) per share for the year, up from their previous forecast of ($0.48). Zacks Investment Research also issued estimates for Soligenix’s Q4 2021 earnings at ($0.09) EPS, FY2022 earnings at ($0.73) EPS and FY2023 earnings at ($0.72) EPS.
Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Friday, November 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.03. Soligenix had a negative net margin of 945.53% and a negative return on equity of 105.58%.
Shares of Soligenix stock opened at $0.87 on Wednesday. The firm has a market capitalization of $34.89 million, a P/E ratio of -2.42 and a beta of 1.13. The company’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.02. The company has a debt-to-equity ratio of 0.63, a current ratio of 7.12 and a quick ratio of 7.12. Soligenix has a fifty-two week low of $0.83 and a fifty-two week high of $2.80.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in Soligenix by 11.7% during the 2nd quarter. Geode Capital Management LLC now owns 244,085 shares of the biopharmaceutical company’s stock worth $270,000 after acquiring an additional 25,549 shares during the period. Millennium Management LLC bought a new position in shares of Soligenix in the 3rd quarter worth $31,000. State Street Corp bought a new position in shares of Soligenix in the 2nd quarter worth $50,000. Goldman Sachs Group Inc. purchased a new stake in shares of Soligenix in the 2nd quarter valued at $60,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of Soligenix in the 3rd quarter valued at $62,000. 10.31% of the stock is currently owned by institutional investors.
Soligenix Company Profile
Soligenix, Inc is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.